FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105996516> ?p ?o ?g. }

• W2105996516 endingPage "114" @default.
• W2105996516 startingPage "107" @default.
• W2105996516 abstract "Background In a phase II study of axitinib for cytokine-refractory metastatic renal cell carcinoma, median overall survival (OS) was 29.9 months (95% CI, 20.3 to not estimable months). Patients and Methods Long-term survival data were collected retrospectively from 52 patients with cytokine-refractory metastatic renal cell carcinoma who received axitinib in a completed phase II study (protocol 1), 11 of whom enrolled in a continuing access protocol (protocol 2), for the current observational study (protocol 3). In a post hoc analysis, the patients were grouped into quartiles based on cycle 1 day 1, 1- to 2-hour post-dose axitinib plasma levels to explore the impact of drug exposure on efficacy. Results The 5-year survival rate was 20.6% (95% CI, 10.9%-32.4%), with a median follow-up of 5.9 years. Frequent all-grade adverse events were fatigue (n = 38; 73.1%), diarrhea (n = 34; 65.4%), hypertension (n = 33; 63.5%), and nausea (n = 33; 63.5%). Quartile 3 patients (axitinib level, 45.2-56.4 ng/mL; n = 12) had the best clinical outcome: objective response rate 82%, median progression-free survival (PFS) 28.3 months, and median OS that was not reached after 5 years. Conclusions Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post–first-dose axitinib plasma concentrations within a specific range." @default.
• W2105996516 created "2016-06-24" @default.
• W2105996516 creator A5001987856 @default.
• W2105996516 creator A5013142762 @default.
• W2105996516 creator A5016800348 @default.
• W2105996516 creator A5025529463 @default.
• W2105996516 creator A5025882028 @default.
• W2105996516 creator A5028789952 @default.
• W2105996516 creator A5030084075 @default.
• W2105996516 creator A5030802759 @default.
• W2105996516 creator A5047852139 @default.
• W2105996516 creator A5059063118 @default.
• W2105996516 creator A5066372195 @default.
• W2105996516 creator A5084631227 @default.
• W2105996516 date "2013-06-01" @default.
• W2105996516 modified "2023-10-17" @default.
• W2105996516 title "Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib" @default.
• W2105996516 cites W1544089991 @default.
• W2105996516 cites W1547252551 @default.
• W2105996516 cites W1968626722 @default.
• W2105996516 cites W1988826649 @default.
• W2105996516 cites W1999966467 @default.
• W2105996516 cites W2017207772 @default.
• W2105996516 cites W2023952988 @default.
• W2105996516 cites W2030884865 @default.
• W2105996516 cites W2062192760 @default.
• W2105996516 cites W2073749087 @default.
• W2105996516 cites W2087137617 @default.
• W2105996516 cites W2096514095 @default.
• W2105996516 cites W2106453307 @default.
• W2105996516 cites W2106797482 @default.
• W2105996516 cites W2106932520 @default.
• W2105996516 cites W2117547860 @default.
• W2105996516 cites W2123769946 @default.
• W2105996516 cites W2129878459 @default.
• W2105996516 cites W2139248078 @default.
• W2105996516 cites W2139848613 @default.
• W2105996516 cites W2149456801 @default.
• W2105996516 cites W2152190103 @default.
• W2105996516 cites W2157262448 @default.
• W2105996516 cites W2158496491 @default.
• W2105996516 cites W2160926061 @default.
• W2105996516 cites W2162424705 @default.
• W2105996516 cites W2165837521 @default.
• W2105996516 cites W2768600953 @default.
• W2105996516 doi "https://doi.org/10.1016/j.clgc.2012.12.004" @default.
• W2105996516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23391371" @default.
• W2105996516 hasPublicationYear "2013" @default.
• W2105996516 type Work @default.
• W2105996516 sameAs 2105996516 @default.
• W2105996516 citedByCount "43" @default.
• W2105996516 countsByYear W21059965162013 @default.
• W2105996516 countsByYear W21059965162014 @default.
• W2105996516 countsByYear W21059965162015 @default.
• W2105996516 countsByYear W21059965162016 @default.
• W2105996516 countsByYear W21059965162017 @default.
• W2105996516 countsByYear W21059965162018 @default.
• W2105996516 countsByYear W21059965162019 @default.
• W2105996516 countsByYear W21059965162020 @default.
• W2105996516 countsByYear W21059965162021 @default.
• W2105996516 countsByYear W21059965162023 @default.
• W2105996516 crossrefType "journal-article" @default.
• W2105996516 hasAuthorship W2105996516A5001987856 @default.
• W2105996516 hasAuthorship W2105996516A5013142762 @default.
• W2105996516 hasAuthorship W2105996516A5016800348 @default.
• W2105996516 hasAuthorship W2105996516A5025529463 @default.
• W2105996516 hasAuthorship W2105996516A5025882028 @default.
• W2105996516 hasAuthorship W2105996516A5028789952 @default.
• W2105996516 hasAuthorship W2105996516A5030084075 @default.
• W2105996516 hasAuthorship W2105996516A5030802759 @default.
• W2105996516 hasAuthorship W2105996516A5047852139 @default.
• W2105996516 hasAuthorship W2105996516A5059063118 @default.
• W2105996516 hasAuthorship W2105996516A5066372195 @default.
• W2105996516 hasAuthorship W2105996516A5084631227 @default.
• W2105996516 hasConcept C121332964 @default.
• W2105996516 hasConcept C126322002 @default.
• W2105996516 hasConcept C126894567 @default.
• W2105996516 hasConcept C142424586 @default.
• W2105996516 hasConcept C143998085 @default.
• W2105996516 hasConcept C2776539811 @default.
• W2105996516 hasConcept C2777472916 @default.
• W2105996516 hasConcept C2779490328 @default.
• W2105996516 hasConcept C2781068499 @default.
• W2105996516 hasConcept C44249647 @default.
• W2105996516 hasConcept C68443243 @default.
• W2105996516 hasConcept C71924100 @default.
• W2105996516 hasConcept C87355193 @default.
• W2105996516 hasConcept C90924648 @default.
• W2105996516 hasConceptScore W2105996516C121332964 @default.
• W2105996516 hasConceptScore W2105996516C126322002 @default.
• W2105996516 hasConceptScore W2105996516C126894567 @default.
• W2105996516 hasConceptScore W2105996516C142424586 @default.
• W2105996516 hasConceptScore W2105996516C143998085 @default.
• W2105996516 hasConceptScore W2105996516C2776539811 @default.
• W2105996516 hasConceptScore W2105996516C2777472916 @default.
• W2105996516 hasConceptScore W2105996516C2779490328 @default.
• W2105996516 hasConceptScore W2105996516C2781068499 @default.
• W2105996516 hasConceptScore W2105996516C44249647 @default.

• next